Mikrobiom bei Leberzirrhose: Pathophysiologie und therapeutische Interventionen

ZusammenfassungDie Leberzirrhose ist weltweit ein zunehmendes Gesundheitsproblem. Die Zusammensetzung des Darmmikrobioms bei Leberzirrhose ist massiv gestört. Strategien zur Modulation des Mikrobioms sind daher ein vielversprechender neuer therapeutischer Ansatz. Antibiotika, Präbiotika, Probiotika und die Stuhltransplantation sind Möglichkeiten, das Mikrobiom zu beeinflussen. Probiotika können insbesondere bei der Behandlung von Komplikationen der Leberzirrhose wirksam sein, es gibt allerdings noch Bedarf an großen, qualitativ hochwertigen Studien, um das therapeutische Potenzial und die möglichen Nebenwirkungen dieser Intervention zu untersuchen.AbstractLiver cirrhosis is a growing public health challenge worldwide. Gut microbiome composition is severely disturbed in cirrhosis. Strategies to modulate the gut microbiome—such as antibiotics, probiotics, prebiotics or faecal transplantation—are promising new tools to influence the microbiome. Probiotics have shown promising results in the treatment of complications of cirrhosis; however, high quality studies are necessary to explore the full potential and possible side effects of gut microbiome modulation in cirrhosis.

• Publication year

  2019

• Venue

  Der Gastroenterologe

• Publication date

  2019-03-26

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s11377-019-0346-1
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Extensive Unexplored Human Microbiome Diversity Revealed by Over 150,000 Genomes from Metagenomes Spanning Age, Geography, and Lifestyle

  2019cited by this paper
• Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES

  2018cited by this paper
• Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis

  2018cited by this paper
• Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy

  2018cited by this paper
• Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis.

  2018cited by this paper
• Mikrobiomassoziierte Lebererkrankungen

  2017cited by this paper
• Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.

  2017cited by this paper
• Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus

  2017cited by this paper
• Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial

  2017cited by this paper
• Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis

  2017cited by this paper
• Probiotics for people with hepatic encephalopathy.

  2017cited by this paper
• Antibiotic prophylaxis in cirrhosis: Good and bad

  2016cited by this paper
• Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis

  2016cited by this paper
• Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis

  2016cited by this paper
• Cirrhosis related functionality characteristic of the fecal microbiota as revealed by a metaproteomic approach

  2016cited by this paper
• Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.

  2016cited by this paper
• Probiotics are helpful in hepatic encephalopathy: a meta‐analysis of randomized trials

  2016cited by this paper
• Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.

  2016cited by this paper
• The Gut Microbiota and Liver Disease

  2015cited by this paper
• Patients Receiving Prebiotics and Probiotics Before Liver Transplantation Develop Fewer Infections Than Controls: A Systematic Review and Meta-Analysis.

  2015cited by this paper
• Immunosuppression and probiotics: are they effective and safe?

  2015cited by this paper
• Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial.

  2015cited by this paper
• Proton pump inhibitors affect the gut microbiome

  2015cited by this paper
• Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study.

  2015cited by this paper
• Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis

  2015cited by this paper
• Proton pump inhibitors alter the composition of the gut microbiota

  2015cited by this paper
• Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver

  2014cited by this paper
• Alterations of the human gut microbiome in liver cirrhosis

  2014cited by this paper
• Effects of probiotic therapy on hepatic encephalopathy in patients with liver cirrhosis: an updated meta-analysis of six randomized controlled trials.

  2014cited by this paper
• Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study

  2014cited by this paper
• Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases.

  2014cited by this paper
• Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites

  2014cited by this paper
• A Systematic Review and Meta-analysis

  2011cited by this paper
• Resistant starch, large bowel fermentation and a broader perspective of prebiotics and probiotics.

  2010cited by this paper
• Störungen des angeborenen Immunsystems bei akuten und chronischen Lebererkrankungen

  2009cited by this paper
• A Meta-Analysis

  2009cited by this paper
• Oral Antibiotic Prophylaxis Reduces Spontaneous Bacterial Peritonitis Occurrence and Improves Short-Term Survival in Cirrhosis: A Meta-Analysis

  2009cited by this paper
• Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics.

  1995cited by this paper
• Jejunal microflora in patients with chronic alcohol abuse.

  1984cited by this paper

• No citing papers are available for this paper.